← Back to Clinical Trials
Recruiting NCT07468864

NCT07468864 Validity of the Turkish Situational Vertigo Questionnaire

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07468864
Status Recruiting
Phase
Sponsor Istanbul Medipol University Hospital
Condition Vestibular Pathology
Study Type OBSERVATIONAL
Enrollment 3 participants
Start Date 2026-02-16
Primary Completion 2026-03-02

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
validity and reliability

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3 participants in total. It began in 2026-02-16 with a primary completion date of 2026-03-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study was planned to examine the validity and reliability of the Turkish version of the Situational Vertigo Questionnaire (SVQ), which is used to evaluate dizziness symptoms frequently seen in vestibular pathologies and triggered by visual or environmental stimuli. The research is designed as a methodological scale adaptation and psychometric evaluation study. The study plans to include individuals aged 18 and over who can read and understand Turkish and have complaints of situational dizziness. The Turkish adaptation process of the SVQ will be carried out using the back-and-forth translation method; a pilot application will be conducted after ensuring linguistic and cultural equivalence. For the psychometric evaluation, the sample size is planned to be at least 10 times the number of items, and participants will be asked to complete the SVQ, as well as the Dizziness Handicap Inventory (DHI), Vertigo Symptom Scale (VSS), and Visual Analog Scale (VAS). To evaluate test-retest reliability, a subgroup of participants will be re-administered the SVQ after 7 days. No invasive procedures will be performed on participants during the research; only survey forms will be used. Written informed consent will be obtained from all participants, and data will be coded and analyzed in accordance with confidentiality principles. It is expected that the findings of this study will contribute to the literature by establishing a valid and reliable measurement tool in Turkish for the evaluation of situational dizziness symptoms and will support clinical evaluation processes.

Eligibility Criteria

Inclusion Criteria: * Presence of dizziness triggered by visual or environmental stimuli * Able to read and write Turkish * Voluntary agreement to participate in the study * Having the mental capacity to give informed consent (Mini Mental State Scale score ≥ 24) Exclusion Criteria: * Individuals with severe cognitive impairment or communication difficulties * Acute neurological disease (stroke, acute MS relapse, etc.) * Having undergone vestibular surgery within the last 3 months

Contact & Investigator

Central Contact

Ebru Sever, MsC, PT

✉ ebru.sever@kocaelisaglik.edu.tr

📞 05336824227

Frequently Asked Questions

Who can join the NCT07468864 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Vestibular Pathology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07468864 currently recruiting?

Yes, NCT07468864 is actively recruiting participants. Contact the research team at ebru.sever@kocaelisaglik.edu.tr for enrollment information.

Where is the NCT07468864 trial being conducted?

This trial is being conducted at Bağcılar, Turkey (Türkiye).

Who is sponsoring the NCT07468864 clinical trial?

NCT07468864 is sponsored by Istanbul Medipol University Hospital. The trial plans to enroll 3 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology